INTREXON CORPORATION (NYSE:XON) Files An 8-K Entry into a Material Definitive Agreement

INTREXON CORPORATION (NYSE:XON) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Story continues below

INTREXON CORP Exhibit
EX-99.1 2 d661617dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Intrexon and Merck KGaA,…
To view the full exhibit click here

About INTREXON CORPORATION (NYSE:XON)

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.

An ad to help with our costs